Platelet Aggregation Inhibitors

"Platelet Aggregation Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.

Descriptor ID	D010975
MeSH Number(s)	D27.505.954.502.780
Concept/Terms	Platelet Aggregation Inhibitors Platelet Aggregation Inhibitors Aggregation Inhibitors, Platelet Inhibitors, Platelet Aggregation Blood Platelet Antiaggregants Antiaggregants, Blood Platelet Platelet Antiaggregants Antiaggregants, Platelet Blood Platelet Aggregation Inhibitors Platelet Inhibitors Platelet Inhibitors Inhibitors, Platelet Antiplatelet Agents Antiplatelet Agents Agents, Antiplatelet Antiplatelet Drugs Drugs, Antiplatelet Platelet Antagonists Platelet Antagonists Antagonists, Platelet Blood Platelet Antagonists Antagonists, Blood Platelet

Below are MeSH descriptors whose meaning is more general than "Platelet Aggregation Inhibitors".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Therapeutic Uses [D27.505.954]
Hematologic Agents [D27.505.954.502]
Platelet Aggregation Inhibitors [D27.505.954.502.780]

Below are MeSH descriptors whose meaning is related to "Platelet Aggregation Inhibitors".

Below are MeSH descriptors whose meaning is more specific than "Platelet Aggregation Inhibitors".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Platelet Aggregation Inhibitors" by people in this website by year, and whether "Platelet Aggregation Inhibitors" was a major or minor topic of these publications.

Bar chart showing 46 publications over 19 distinct years, with a maximum of 7 publications in 2018

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2002	0	2	2
2003	1	0	1
2004	0	1	1
2005	0	1	1
2008	1	0	1
2009	0	2	2
2010	1	0	1
2011	1	5	6
2012	3	1	4
2013	1	1	2
2014	1	2	3
2015	1	0	1
2016	1	1	2
2017	2	0	2
2018	6	1	7
2019	3	1	4
2020	2	1	3
2021	1	0	1
2022	1	1	2

Below are the most recent publications written about "Platelet Aggregation Inhibitors" by people in Profiles.

Lopez-Candales A, Norgard N. Will the new pharmaceutical lipid-aspirin complex formulation restore the once lost trust of aspirin on cardiovascular protection? Postgrad Med. 2022 08; 134(6):573-575.

View in: PubMed
Park J, Jung JH, Choi EK, Lee SW, Kwon S, Lee SR, Kang J, Han KD, Park KW, Oh S, Lip GYH. Comparison of early clinical outcomes between dual antiplatelet therapy and triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. PLoS One. 2022; 17(2):e0264538.

View in: PubMed
Duconge J, Santiago E, Hernandez-Suarez DF, Moner? M, L?pez-Reyes A, Rosario M, Renta JY, Gonz?lez P, Ileana Fern?ndez-Morales L, Antonio V?lez-Figueroa L, Arce O, Mar?n-Maldonado F, Nu?ez H, Melin K, Scott SA, Rua?o G. Pharmacogenomic polygenic risk score for clopidogrel responsiveness among Caribbean Hispanics: A candidate gene approach. Clin Transl Sci. 2021 11; 14(6):2254-2266.

View in: PubMed
Park J, Choi EK, Han KD, Kim B, Choi YJ, Lee SR, Kang J, Cha MJ, Park KW, Oh S, Lip GYH. Outcomes in relation to antithrombotic therapy among patients with atrial fibrillation after percutaneous coronary intervention. PLoS One. 2020; 15(10):e0240161.

View in: PubMed
Hernandez-Suarez DF, Melin K, Marin-Maldonado F, Nunez HJ, Gonzalez AF, Gonzalez-Sepulveda L, Rivas-Tumanyan S, Naik H, Rua?o G, Scott SA, Duconge J. Implementing a pharmacogenetic-driven algorithm to guide dual antiplatelet therapy (DAPT) in Caribbean Hispanics: protocol for a non-randomised clinical trial. BMJ Open. 2020 08 06; 10(8):e038936.

View in: PubMed
Limdi NA, Cavallari LH, Lee CR, Hillegass WB, Holmes AM, Skaar TC, Pisu M, Dillon C, Beitelshees AL, Empey PE, Duarte JD, Diaby V, Gong Y, Johnson JA, Graves J, Garbett S, Zhou Z, Peterson JF. Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data. Pharmacogenomics J. 2020 10; 20(5):724-735.

View in: PubMed
Roshandel G, Khoshnia M, Poustchi H, Hemming K, Kamangar F, Gharavi A, Ostovaneh MR, Nateghi A, Majed M, Navabakhsh B, Merat S, Pourshams A, Nalini M, Malekzadeh F, Sadeghi M, Mohammadifard N, Sarrafzadegan N, Naemi-Tabiei M, Fazel A, Brennan P, Etemadi A, Boffetta P, Thomas N, Marshall T, Cheng KK, Malekzadeh R. Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial. Lancet. 2019 08 24; 394(10199):672-683.

View in: PubMed
Dahl L, Schultz A, McGibbon E, Brownlie J, Cook C, Elbarouni B, Katz A, Nguyen T, Sawatzky JA, Sinclaire M, Throndson K, Prior HJ, Fransoo R. Cardiovascular Medication Use and Long-Term Outcomes of First Nations and Non-First Nations Patients Following Diagnostic Angiography: A Retrospective Cohort Study. J Am Heart Assoc. 2019 08 20; 8(16):e012040.

View in: PubMed
Rosenson RS, Chen Q, Najera SD, Krishnan P, Lee ML, Cho DJ. Ticagrelor improves blood viscosity-dependent microcirculatory flow in patients with lower extremity arterial disease: the Hema-kinesis clinical trial. Cardiovasc Diabetol. 2019 06 07; 18(1):77.

View in: PubMed
Park J, Choi EK, Han KD, Choi YJ, Lee E, Choe W, Lee SR, Cha MJ, Lim WH, Kang J, Park KW, Oh S, Lip GYH. Temporal trends in prevalence and antithrombotic treatment among Asians with atrial fibrillation undergoing percutaneous coronary intervention: A nationwide Korean population-based study. PLoS One. 2019; 14(1):e0209593.

View in: PubMed

People

Explore

Similar Concepts

Top Journals